Our lab integrates machine learning and high-throughput biochemistry to study how proteins selectively recognise their substrates, how this process is perturbed in cancer and how it can be hijacked to find highly selective and mutant-specific drugs to overcome drug resistance.
Targeted therapies have significantly improved outcomes for patients and shifted the clinical and biological goal towards targeting evolutionary trajectories and overcoming resistance.
To overcome these challenges, it is critical to repurpose existing cancer drugs and design news ones with higher selectivity, lower toxicity and less prone to resistance.
In our lab we combine and develop technology ranging from peptide display, deep sequencing, machine learning, drug design and functional protein biochemistry with the long-term-goal to make an impact in our understanding and treatment of cancer and drug resistance.
Our previous studies have taught us general principles in cellular signalling specificity, which we are now using to investigate unexplored cancer signalling, molecular recognition and epistasis, novel therapeutics and predict and overcome drug resistance.
We have three positions open within the Creixell Group.
Drugging the undruggable: Therapeutically targeting key drivers of pro- and anti-oncogenic signaling in brain cancer, lung cancer and leukemia. Find out more here.
Learning from and outperforming nature: Computationally reconstructing and experimentally screening ancestral proteins to understand the evolution of signaling systems. Find out more here.
Supercharging nature’s biochemical reactions for therapeutic and climate change applications. Find out more here.
Ready to apply? Deadline is 13th November 2023